A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
Bristol-Myers Squibb
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- RECRUITING
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 325
- sponsor
- Bristol-Myers Squibb
- conditions
- Alzheimer Disease; Psychosis
- interventions
- DRUG: KarXT; DRUG: KarX-EC; DRUG: KarXT + KarX-EC Arm Matching Placebo
- start date
- 2026-03-25
- start date type
- ACTUAL
- primary completion date
- 2028-02-21
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT06947941
- Published
- Apr 27, 2025
- Updated
- Jun 30, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT06947941
- Categories
- Alzheimer Disease, Psychosis
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials